# EDGAR Filing Document

**Accession Number:** 0000310158
**File Stem:** 0001193125-25-326810
**Filing Date:** 2025-12
**Character Count:** 8240
**Document Hash:** 6c3394ceb1a7f2591073601e0fb816b6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-326810.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001193125-25-326810

**CONFORMED SUBMISSION TYPE**: SC TO-T/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**GROUP MEMBERS**: CAYMUS PURCHASER, INC

**GROUP MEMBERS**: MERCK SHARPE & DOHME LLC

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cidara Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001610618
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461537286
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88806
- **FILM NUMBER:** 251587553

**BUSINESS ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-752-6170

**MAIL ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** K2 THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20140611
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merck & Co., Inc.
- **CENTRAL INDEX KEY:** 0000310158
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 221918501
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A

**BUSINESS ADDRESS:**
- **STREET 1:** 126 EAST LINCOLN AVENUE
- **STREET 2:** P.O. BOX 2000
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065
- **BUSINESS PHONE:** 908-740-4000

**MAIL ADDRESS:**
- **STREET 1:** 126 EAST LINCOLN AVENUE
- **STREET 2:** P.O. BOX 2000
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merck & Co. Inc.
- **DATE OF NAME CHANGE:** 20091103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SCHERING PLOUGH CORP
- **DATE OF NAME CHANGE:** 19920703

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE TO** 

**TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**Amendment No. 2** 

## CIDARA THERAPEUTICS, INC.
**(Name of Subject Company — Issuer)** 

## CAYMUS PURCHASER, INC.
**(Offeror)** 

**A wholly owned subsidiary of** 

## MERCK SHARP & DOHME LLC
**(Parent of Offeror)** 

**A Wholly Owned Subsidiary of** 

## MERCK & CO., INC.
**(Parent of Offeror)** 

**(Names of Filing Persons (identifying status as offeror, issuer or other person))** 

**Common Stock, par value $0.0001 per share** 

**Series A Convertible Voting Preferred Stock, par value $0.0001 per share** 

**(Title of Class of Securities)** 

**171757206** 

**(CUSIP Number of Class of Securities)** 

**Kelly E.W. Grez** 

**Corporate Secretary, Merck & Co., Inc.** 

**126 East Lincoln Avenue Rahway, NJ 07065** 

**(908) 740-4000** 

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)** 

***Copies to:***

**Saee Muzumdar** 

**Sebastian L. Fain** 

**Gibson, Dunn & Crutcher LLP** 

**200 Park Avenue New York, NY 10166** 

**(212) 351-4035** 

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ Third-party tender offer subject to Rule 14d-1.

☐ Issuer tender offer subject to Rule 13e-4.

☐ Going-private transaction subject to Rule 13e-3.

☐ Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

------

This Amendment No. 2 (this **"Amendment**") amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on December 5, 2025 (together with any subsequent amendments and supplements thereto, the **"Schedule TO**"), by Caymus Purchaser, Inc., a Delaware corporation ("**Purchaser**") and a wholly owned indirect subsidiary of Merck Sharp & Dohme LLC, a New Jersey limited liability company ("**Parent**"), Parent and Merck & Co., Inc., a New Jersey corporation ("**Merck**"). The Schedule TO relates to the offer by Purchaser to acquire (i) all of the outstanding shares of common stock, par value $0.0001 per share (the "**Common Shares**") of Cidara Therapeutics, Inc., a Delaware corporation ("**Cidara**"), for $221.50 per Common Share, and (ii) all of the outstanding shares of Series A Convertible Voting Preferred Stock, par value $0.0001 per share (the "**Series A Shares**") of Cidara for $15,505.00 per Series A Share, in each case, in cash, without interest, subject to any applicable withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 5, 2025 (as it may be amended or supplemented from time to time, the "**Offer to Purchase**"), in the related Letter of Transmittal (as it may be amended or supplemented from time to time, the "**Letter of Transmittal**") and in the related Notice of Guaranteed Delivery (as it may be amended or supplemented from time to time, the "**Notice of Guaranteed Delivery**" and, together with the Offer to Purchase and the Letter of Transmittal, the "**Offer**"), copies of which are attached hereto as Exhibits (a)(1)(i), (a)(1)(ii) and (a)(1)(iii), respectively.

All of the information set forth in the Offer to Purchase is incorporated by reference herein in response to Items 1 through 9 and Item 11 of this Schedule TO, and is supplemented by the information specifically provided in this Schedule TO.

Except as otherwise set forth in this Amendment, all terms of the Offer and all other disclosures set forth in the Schedule TO and the exhibits thereto remain unchanged and are hereby expressly incorporated into this Amendment by reference. This Amendment should be read together with the Schedule TO. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Schedule TO and the Offer to Purchase.

**Item 11. *Additional Information*.** 

The disclosure in the Offer to Purchase and Item 11 of the Schedule TO, to the extent such Item incorporates by reference the information contained in the Offer to Purchase, is hereby amended and supplemented by amending and restating the second paragraph under the heading "*U.S. Antitrust*" in "-Section 16-Certain Legal Matters; Regulatory Approvals" of the Offer to Purchase as follows:

"On December 19, 2025, effective as of 10:30 a.m., Eastern Time, the FTC granted early termination of the waiting period under the HSR Act. Accordingly, the condition to the Offer requiring that the waiting period (or any extension thereof) applicable to the Offer under the HSR Act shall have expired or been terminated has been satisfied."

------

**SIGNATURES** 

After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
|  | **CAYMUS PURCHASER, INC.** | **CAYMUS PURCHASER, INC.** |
|  | By: | /s/ Kelly E.W. Grez |
|  |  | Name: Kelly E.W. Grez |
|  |  | Title: Secretary |
|  | **MERCK & CO., INC.** | **MERCK & CO., INC.** |
|  | By: | /s/ Sunil A. Patel |
|  |  | Name: Sunil A. Patel |
|  |  | Title: Senior Vice President, Head of Business Development |
|  | **MERCK SHARP & DOHME LLC** | **MERCK SHARP & DOHME LLC** |
| Date: December 19, 2025 | By: | /s/ Sunil A. Patel |
|  |  | Name: Sunil A. Patel |
|  |  | Title: Senior Vice President, Head of Business Development |

---